TWI655433B - 川崎氏症之診斷與治療 - Google Patents

川崎氏症之診斷與治療 Download PDF

Info

Publication number
TWI655433B
TWI655433B TW105135195A TW105135195A TWI655433B TW I655433 B TWI655433 B TW I655433B TW 105135195 A TW105135195 A TW 105135195A TW 105135195 A TW105135195 A TW 105135195A TW I655433 B TWI655433 B TW I655433B
Authority
TW
Taiwan
Prior art keywords
amount
sample
individual
biomarker
treatment
Prior art date
Application number
TW105135195A
Other languages
English (en)
Chinese (zh)
Other versions
TW201706600A (zh
Inventor
陳垣崇
Yuan Tsong Chen
鄔哲源
Jer Yuarn Wu
柯泰名
Tai Ming Ko
郭和昌
Ho Chang Kuo
張正成
Jeng Sheng Chang
Original Assignee
中央研究院
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中央研究院, Academia Sinica filed Critical 中央研究院
Publication of TW201706600A publication Critical patent/TW201706600A/zh
Application granted granted Critical
Publication of TWI655433B publication Critical patent/TWI655433B/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5418—IL-7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/328—Vasculitis, i.e. inflammation of blood vessels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW105135195A 2014-07-24 2015-07-24 川崎氏症之診斷與治療 TWI655433B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028633P 2014-07-24 2014-07-24
US62/028,633 2014-07-24

Publications (2)

Publication Number Publication Date
TW201706600A TW201706600A (zh) 2017-02-16
TWI655433B true TWI655433B (zh) 2019-04-01

Family

ID=55163743

Family Applications (2)

Application Number Title Priority Date Filing Date
TW105135195A TWI655433B (zh) 2014-07-24 2015-07-24 川崎氏症之診斷與治療
TW104124138A TWI598586B (zh) 2014-07-24 2015-07-24 川崎氏症之診斷與治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW104124138A TWI598586B (zh) 2014-07-24 2015-07-24 川崎氏症之診斷與治療

Country Status (7)

Country Link
US (1) US10983133B2 (enExample)
JP (1) JP6779200B2 (enExample)
KR (1) KR102453756B1 (enExample)
CN (1) CN106796221B (enExample)
CA (1) CA2955214C (enExample)
TW (2) TWI655433B (enExample)
WO (1) WO2016014761A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI683905B (zh) * 2017-11-21 2020-02-01 長庚醫療財團法人高雄長庚紀念醫院 用於檢測川崎氏病的方法及套組以及用於治療川崎氏病的方法
KR102056405B1 (ko) * 2018-04-05 2019-12-16 (주)메디젠휴먼케어 Ebf2 유전자 다형성을 이용한 가와사키병 발병 예측 방법
AU2019317990B2 (en) * 2018-08-04 2025-04-24 Imperial College Innovations Limited Method of identifying a subject having Kawasaki disease
CN113834939A (zh) * 2021-09-18 2021-12-24 胜亚生物科技(厦门)有限公司 一种用于检测川崎病及疗效评估的试剂、试剂盒及应用
WO2024037387A1 (en) * 2022-08-19 2024-02-22 Tianjin Yunjian Medical Technology Co., Ltd. Blood biomarkers and methods for diagnosis of acute kawasaki disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189698A1 (en) * 2008-08-28 2011-08-04 The Regents Of The University Of California Protein Biomarkers and Methods for Diagnosing Kawasaki Disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3888224T2 (de) 1987-04-24 1994-07-21 Teijin Ltd Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
WO2012112315A2 (en) * 2011-02-20 2012-08-23 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of kawasaki disease
US9869673B2 (en) 2011-04-15 2018-01-16 The Children's Medical Center Corporation Diagnostic markers and therapeutic targets of kawasaki disease
LT2852615T (lt) * 2012-05-22 2019-02-11 Bristol-Myers Squibb Company Il-17a/f il-23 bispecifiniai antikūnai ir jų panaudojimai
WO2014043397A1 (en) 2012-09-12 2014-03-20 Indiana University Research & Technology Corporation Material and methods for diagnosing and treating kawasaki disease and kls

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189698A1 (en) * 2008-08-28 2011-08-04 The Regents Of The University Of California Protein Biomarkers and Methods for Diagnosing Kawasaki Disease

Also Published As

Publication number Publication date
WO2016014761A1 (en) 2016-01-28
TW201617613A (zh) 2016-05-16
KR20170039139A (ko) 2017-04-10
JP2017524933A (ja) 2017-08-31
KR102453756B1 (ko) 2022-10-12
TW201706600A (zh) 2017-02-16
US10983133B2 (en) 2021-04-20
JP6779200B2 (ja) 2020-11-04
CN106796221B (zh) 2019-12-17
CN106796221A (zh) 2017-05-31
TWI598586B (zh) 2017-09-11
US20170153250A1 (en) 2017-06-01
CA2955214C (en) 2023-03-21
CA2955214A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
US10338083B2 (en) Pathway specific markers for diagnosing irritable bowel syndrome
US12205677B2 (en) System and method for analysis of biological data
TWI655433B (zh) 川崎氏症之診斷與治療
EP3729101B1 (en) Workflow for risk assessment and patient management using procalcitonin and proadrenomedullin
JP2013527444A (ja) 抗体を検出するための方法
Song et al. Single molecule measurements of tumor necrosis factor α and interleukin-6 in the plasma of patients with Crohn's disease
WO2016129631A1 (ja) 川崎病の検査方法およびキット
WO2019117132A1 (ja) がん免疫療法の予後予測のためのバイオマーカー
CN111065927B (zh) 作为危重患者的治疗监测标记物的pro-adm
US20200271666A1 (en) Proadrenomedullin as indicator for renal replacement therapy in critically ill patients
US20180011110A1 (en) Methods and Compositions in Diagnosis of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
CN117529664A (zh) 用于预测脓毒症和脓毒性休克的方法
JP7461346B2 (ja) 重度の外傷性脳損傷の血液バイオマーカー
WO2025244092A1 (ja) アトピー性皮膚炎患者へのデュピルマブの投与の有効性を予測する方法及びキット
WO2022122959A1 (en) Use of cd177 as biomarker of worsening in patients suffering from covid-19
WO2021210651A1 (ja) 重症薬疹のタンパク質診断バイオマーカー
HK40029756B (zh) 使用降钙素原和中区肾上腺髓质素原的风险评估和患者管理的工作流程